Literature DB >> 26370256

Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy.

Susumu Saigusa1, Yuji Toiyama2, Koji Tanaka2, Yasuhiro Inoue2, Koichiro Mori2, Shozo Ide2, Hiroki Imaoka2, Mikio Kawamura2, Yasuhiko Mohri2, Masato Kusunoki2.   

Abstract

BACKGROUND: CD26 is a transmembrane glycoprotein whose role in various types of malignancies, along with the potential therapeutic and diagnostic targets, has been evaluated. Preoperative chemoradiotherapy (CRT) is an effective tool for local control of rectal cancer, but the rate of disease recurrence remains high. The aim of this study was to clarify the association between CD26 expression and rectal cancer after preoperative CRT.
METHODS: A total of 85 patients with rectal cancer who had undergone preoperative CRT were enrolled in this study. We investigated CD26 expression in residual tumors and the surrounding stromal tissue using immunohistochemistry. Additionally, stromal CD26 gene expression was assessed by real-time quantitative polymerase chain reaction.
RESULTS: Patients with high CD26 expression in cancer tissue more frequently had serosal invasion, vascular invasion, and a poor pathological response. High expression of CD26 in the tumor stroma was significantly correlated with histology and tumor recurrence. High CD26 expression in the stroma, but not the tumor itself, was significantly correlated with a poor prognosis. Patients expressing CD26 in the tumor stroma, based on transcriptional analysis, also had a significantly poorer prognosis than those without the expression. In multivariate analysis, lymph node metastasis and high stromal CD26 expression were identified as independent prognostic factors in patients with rectal cancer after neoadjuvant CRT.
CONCLUSION: Stromal CD26 expression after preoperative CRT was significantly associated with tumor recurrence and prognosis in rectal cancer patients. Our data suggest that stromal CD26 plays an important role and is a potential therapeutic target in tumor relapse.

Entities:  

Keywords:  CD26; Chemoradiotherapy; Prognosis; Rectal cancer; Tumor stroma

Mesh:

Substances:

Year:  2015        PMID: 26370256     DOI: 10.1007/s10147-015-0902-8

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  39 in total

1.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

2.  Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.

Authors:  Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

3.  Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue.

Authors:  T Bogenrieder; C L Finstad; R H Freeman; C N Papandreou; H I Scher; A P Albino; V E Reuter; D M Nanus
Journal:  Prostate       Date:  1997-12-01       Impact factor: 4.104

4.  T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition.

Authors:  Nam H Dang; Ugur Aytac; Kazuya Sato; Susan O'Brien; Jos Melenhorst; Chikao Morimoto; A John Barrett; Jeffrey J Molldrem
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

5.  The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.

Authors:  Koen C M J Peeters; Corrie A M Marijnen; Iris D Nagtegaal; Elma Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm Rutten; Lars Pahlman; Bengt Glimelius; Jan Willem Leer; Cornelis J H van de Velde
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

Review 6.  Seprase: an overview of an important matrix serine protease.

Authors:  Pamela O'Brien; Brendan F O'Connor
Journal:  Biochim Biophys Acta       Date:  2008-01-26

Review 7.  On the origin of serum CD26 and its altered concentration in cancer patients.

Authors:  Oscar J Cordero; Francisco J Salgado; Montserrat Nogueira
Journal:  Cancer Immunol Immunother       Date:  2009-06-26       Impact factor: 6.968

8.  Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy.

Authors:  Susumu Saigusa; Yasuhiro Inoue; Koji Tanaka; Yoshinaga Okugawa; Yuji Toiyama; Keiichi Uchida; Yasuhiko Mohri; Masato Kusunoki
Journal:  Mol Clin Oncol       Date:  2013-09-20

9.  CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion.

Authors:  P A Havre; M Abe; Y Urasaki; K Ohnuma; C Morimoto; N H Dang
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

View more
  4 in total

Review 1.  Tissue-Based Markers as a Tool to Assess Response to Neoadjuvant Radiotherapy in Rectal Cancer-Systematic Review.

Authors:  Edgaras Smolskas; Goda Mikulskytė; Ernestas Sileika; Kestutis Suziedelis; Audrius Dulskas
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

2.  Suppression of CD26 inhibits growth and metastasis of pancreatic cancer.

Authors:  Chunxiang Ye; Xiuyun Tian; Guanjun Yue; Liang Yan; Xiaoya Guan; Shan Wang; Chunyi Hao
Journal:  Tumour Biol       Date:  2016-10-07

3.  Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer.

Authors:  Gustavo A Arias-Pinilla; Angus G Dalgleish; Satvinder Mudan; Izhar Bagwan; Anthony J Walker; Helmout Modjtahedi
Journal:  Sci Rep       Date:  2020-01-17       Impact factor: 4.379

Review 4.  CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology.

Authors:  Emi Kawakita; Daisuke Koya; Keizo Kanasaki
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.